The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...

Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, was recognized on ...

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

Vertex VERX shares have skyrocketed 107.3% in the past 12 months, outperforming the Zacks Computer Technology sector, Zacks Internet Software industry and the S&P 500’s return of 38.1%, 40.3% and 26.8 ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and ...

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...

Vertex (VERX – Research Report) received a Hold rating and price target from Raymond James analyst Alexander Sklar today. The company’s ...

Vertex, Inc. (NASDAQ:VERX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the thirteen research firms that are covering the company, MarketBeat.com reports. Four ...

Vertex Global Services partners with UK-based Arish Global Services to create over 5,000 jobs in India, boosting the ...

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell disease and transfusion-dependent beta thalassemia.